NuCana (NASDAQ:NCNA) Trading 0.9% Higher – What’s Next?

NuCana PLC Sponsored ADR (NASDAQ:NCNA)’s share price rose 0.9% during mid-day trading on Thursday . The company traded as high as $2.17 and last traded at $2.15. Approximately 12,273 shares traded hands during mid-day trading, a decline of 68% from the average daily volume of 38,089 shares. The stock had previously closed at $2.13.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NuCana in a report on Tuesday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, NuCana currently has an average rating of “Sell”.

NuCana Stock Up 0.9%

The firm has a market cap of $8.94 million, a price-to-earnings ratio of -0.02 and a beta of 1.79. The business has a 50 day moving average of $1.94 and a 200 day moving average of $3.11.

Institutional Trading of NuCana

An institutional investor recently raised its position in NuCana stock. FNY Investment Advisers LLC grew its stake in shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA) by 210.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 10,000 shares of the company’s stock after buying an additional 6,774 shares during the period. FNY Investment Advisers LLC owned 33.33% of NuCana worth $36,000 as of its most recent SEC filing. 44.00% of the stock is owned by hedge funds and other institutional investors.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.